Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence (VANISH-2)

This study has been completed.
Information provided by (Responsible Party):
BTG International Inc.
ClinicalTrials.gov Identifier:
First received: October 22, 2010
Last updated: February 19, 2015
Last verified: February 2015
Results First Received: December 20, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Varicose Veins
Interventions: Drug: polidocanol injectable foam, 0.125%
Drug: polidocanol injectable foam, 0.5%
Drug: polidocanol injectable foam, 1.0%
Drug: Vehicle

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Three (3) patients were randomized but never treated.

Reporting Groups
Vehicle Vehicle: Injection of vehicle comparator
Polidocanol Injectable Foam, 0.125% active placebo for blinding of therapeutic polidocanol dose
Polidocanol Injectable Foam, 0.5% lower experimental polidocanol dose
Polidocanol Injectable Foam, 1.0% 1.0% polidocanol foam injection

Participant Flow:   Overall Study
    Vehicle     Polidocanol Injectable Foam, 0.125%     Polidocanol Injectable Foam, 0.5%     Polidocanol Injectable Foam, 1.0%  
STARTED     59     58     60     58  
Patients Receiving Blinded Treatment     57     57     60     58  
COMPLETED     56     57     60     57  
NOT COMPLETED     3     1     0     1  
Withdrew consent prior to randomization                 2                 1                 0                 0  
Lost to Follow-up                 0                 0                 0                 1  
Withdrew Consent                 1                 0                 0                 0  

  Baseline Characteristics

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Patient-Reported Symptoms of Varicose Veins (VVSymQ Score)   [ Time Frame: 8 weeks ]

2.  Secondary:   Change From Baseline to 8 Weeks in Appearance as Rated by Patient (PA-V3)   [ Time Frame: 8 weeks ]

3.  Secondary:   Change From Baseline at 8 Weeks Post-Treatment in IPR-V3 Score--Physician Photographic Review of Appearance   [ Time Frame: 8 weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: David Wright MBBS
Organization: BTG International Inc.
phone: 610-278-1660
e-mail: david.wright@btgplc.com

Responsible Party: BTG International Inc.
ClinicalTrials.gov Identifier: NCT01231373     History of Changes
Other Study ID Numbers: VAP.VV016
Study First Received: October 22, 2010
Results First Received: December 20, 2013
Last Updated: February 19, 2015
Health Authority: United States: Food and Drug Administration